ArticleImmunoHorizons2026
Respiratory syncytial virus mRNA vaccine-induced immunity and protection against subgroups A and B in mice.
Article in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Respiratory syncytial virus (RSV) is a major global cause of severe lower respiratory tract infections in infants and older adults. RSV has 2 subgroups, A (RSV-A) and B (RSV-B), which circulate together with different patterns of dominance. A vaccine must protect against both. Reccently, prefusion F protein-based vaccines for maternal and older adult populations achieved ∼70% efficacy, and Moderna's mRNA vaccine for older adults further underscores the potential of mRNA platforms. Here, we report preclinical evaluation of VER-027, a novel mRNA vaccine encoding prefusion F proteins from both RSV-A and RSV-B. A 2-dose intramuscular regimen induced high pre-F-specific immunoglobulin G (IgG) titers, potent neutralizing activity against both subgroups, and robust F85-93-specific CD8+ T cell responses. All mice vaccinated with this mRNA vaccine were fully protected against RSV-A and RSV-B challenge. These findings support VER-027 as a strong candidate for clinical development as a dual-subgroup RSV vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.